ASCO 2021: Cobozantinib plus nivolumab combination for non-clear cell kidney cancer
The cabozantinib/nivolumab combination has been shown to be effective at [...]
Nivolumab/cabozantinib combination approved in EU for first-line kidney cancer treatment
The European Commission has approved the use of the nivolumab [...]
Nivolumab/cabozantinib combination recommended for EMA approval for first-line kidney cancer
The Committee for Medicinal Products for Human Use (CHMP) of [...]
ASCO GU 2021: Long-term follow-up of kidney cancer patients on nivolumab plus ipilimumab combination
Long-term follow-up data from the CheckMate-214 study of the nivolumab [...]
ASCO GU 2021: Nivolumab plus ipilimumab combination in patients with non-clear cell kidney cancer
Data from the CheckMate-920 study on the safety and effectiveness [...]
ASCO GU 2021: Nivolumab plus cabozantinib combination for the first-line treatment of advanced kidney cancer
The past couple of years has seen a number of [...]
Cabozantinib plus nivolumab granted FDA approval for first-line treatment of advanced kidney cancer
The Food and Drug Administration (FDA) in the United States has [...]
Nivolumab plus ipilimumab for first-line treatment of advanced kidney cancer: Extended 4-year follow-up
Four-year follow up data are now available from the CheckMate [...]
Neoadjuvant nivolumab for patients with non-metastatic high risk kidney cancer
A recent phase 1 trial showed that treatment with nivolumab [...]
γ-Glutamyltransferase as a biomarker in patients on nivolumab for metastatic kidney cacner
A protein called γ-glutamyltransferase can predict survival in patients with [...]
